Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine Loop

30 Nov 2022

Abstract excerpt

The advent of chimeric antigen receptor (CAR) T cells expedited the field of cancer immunotherapy enabling durable remissions in patients with refractory hematological malignancies. T cells redirected for universal cytokine-mediated killing (TRUCKs), commonly referred to as "fourth generation" CAR T-cells, are designed to release engineered payloads upon CAR-induced T-cell activation. Building on the TRUCK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Integrated Circuits and Semiconductor Failure Analysis
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36497099
DOI: 10.3390/cells11233839

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine LoopPMID 36497099Read ↗

Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cellsSemantic proximity Read ↗

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.Semantic proximity Read ↗

Single-Cell Analysis of CAR-T Cell Activation Reveals A Mixed T H 1/T H 2 Response Independent of DifferentiationSemantic proximity Read ↗

Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment EfficacySemantic proximity Read ↗

Antiviral T-cell Biofactory platform for SARS-CoV-2Semantic proximity Read ↗

<i>First-in-class</i> Transactivator-Free, Doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B-cell lymphomasSemantic proximity Read ↗

Engineered NKG2C <sup>+</sup> NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndromeSemantic proximity Read ↗

Application and Design of Switches Used in CARSemantic proximity Read ↗

CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities.Semantic proximity Read ↗

CAR-T-Cell Therapy: Present Progress and Future strategiesSemantic proximity Read ↗

Sense-and-respond payload delivery using a novel antigen-inducible promoter improves suboptimal CAR-T activationSemantic proximity Read ↗

CAR T cell engineering impacts antigen-independent activation and co-inhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.